Korro Bio (NASDAQ:KRRO) Shares Gap Up to $73.37

Korro Bio, Inc. (NASDAQ:KRRO)’s share price gapped up before the market opened on Wednesday . The stock had previously closed at $73.37, but opened at $75.22. Korro Bio shares last traded at $73.99, with a volume of 763 shares traded.

Analyst Ratings Changes

KRRO has been the subject of a number of research analyst reports. Royal Bank of Canada boosted their price target on Korro Bio from $70.00 to $90.00 and gave the stock an “outperform” rating in a report on Wednesday, March 27th. BMO Capital Markets restated an “outperform” rating and set a $120.00 price objective on shares of Korro Bio in a research report on Tuesday, March 26th. HC Wainwright boosted their price objective on Korro Bio from $100.00 to $115.00 and gave the stock a “buy” rating in a research report on Thursday, March 28th. Finally, Piper Sandler restated an “overweight” rating and set a $180.00 price objective on shares of Korro Bio in a research report on Wednesday, March 27th.

Korro Bio Trading Up 1.2 %

The company’s 50-day moving average price is $63.14. The company has a market cap of $595.24 million, a PE ratio of -0.78 and a beta of 2.18.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. acquired a new position in shares of Korro Bio in the 4th quarter valued at about $12,988,000. Eventide Asset Management LLC acquired a new position in Korro Bio during the 4th quarter worth approximately $26,185,000. 72 Investment Holdings LLC acquired a new position in Korro Bio during the 4th quarter worth approximately $13,269,000. Point72 Asset Management L.P. acquired a new position in Korro Bio during the 4th quarter worth approximately $12,741,000. Finally, Verition Fund Management LLC acquired a new position in Korro Bio during the 4th quarter worth approximately $2,784,000. 13.18% of the stock is owned by institutional investors and hedge funds.

About Korro Bio

Korro Bio, Inc, a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. Korro Bio, Inc is based in Cambridge, Massachusetts.